Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ripretinib |
| Trade Name | Qinlock |
| Synonyms | DCC-2618|DCC2618 |
| Drug Descriptions |
Qinlock (ripretinib) is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183, PMID: 31085175, PMID: 31201392). Qinlock (ripretinib) is FDA approved for use in patients with advanced gastrointestinal stromal tumor who received 3 or more prior kinase inhibitor therapies (FDA.gov) |
| DrugClasses | KIT Inhibitor 57 PDGFR-alpha Inhibitor 10 |
| CAS Registry Number | 1442472-39-0 |
| NCIT ID | C124067 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Binimetinib + Ripretinib | Binimetinib Ripretinib | 0 | 1 |
| Everolimus + Ripretinib | Everolimus Ripretinib | 1 | 0 |
| Inlexisertib + Ripretinib | Inlexisertib Ripretinib | 0 | 1 |
| Olaparib + Ripretinib | Olaparib Ripretinib | 1 | 0 |
| Repaglinide + Ripretinib | Repaglinide Ripretinib | 0 | 1 |
| Ripretinib | Ripretinib | 81 | 4 |
| Ripretinib + Selumetinib | Ripretinib Selumetinib | 0 | 0 |
| Ripretinib + Sunitinib | Ripretinib Sunitinib | 5 | 0 |
| Ripretinib + Trametinib | Ripretinib Trametinib | 0 | 0 |